CN108144039A - A kind of drug for treating postmenopausal osteoporosis - Google Patents
A kind of drug for treating postmenopausal osteoporosis Download PDFInfo
- Publication number
- CN108144039A CN108144039A CN201810057625.XA CN201810057625A CN108144039A CN 108144039 A CN108144039 A CN 108144039A CN 201810057625 A CN201810057625 A CN 201810057625A CN 108144039 A CN108144039 A CN 108144039A
- Authority
- CN
- China
- Prior art keywords
- bone
- drug
- caltrate
- postmenopausal osteoporosis
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention belongs to clinical medicine technical fields, disclose a kind of drug for treating postmenopausal osteoporosis, the drug of the treatment postmenopausal osteoporosis is circle element bone peptide 10g and Caltrate D 600mg compositions.The plain bone peptide joint Caltrate D of oral circle of the present invention has better protecting effect project implementation convenience, safety, the economy than Caltrate D to post menopausal sclerotin pine patient bone loss; it is with obvious effects; can be that further the loosely-related bone lesion of research post menopausal sclerotin sulphur is not fixed basic, learning value and social benefit are apparent.
Description
Technical field
The invention belongs to clinical medicine technical field more particularly to a kind of drugs for treating postmenopausal osteoporosis.
Background technology
Osteoporosis is a kind of metabolic disease, it is characterized in that sliding amount caused by bon e formation is insufficient, bone information is excessive
It reduces and the deterioration of bone micro-structure, consequence increases bone brittleness and fracture neurological susceptibility.Osteoporosis relies primarily on west at present
The treatment of medical chemistry synthetic drug, there are certain side effect, and it is expensive.Collagen peptide is rich in the sweet ammonia that human body needs
The amino acid such as acid, proline, hydroxyproline have the higher property digested and assimilated and safety.Collagen peptide mixer is as oral
Replenishers have shown good treatment in terms of Bones and joints are restored) it does:Oral collagen peptide or oral collagen peptide joint
Can calcium treat Postmenopausal Osteoporosis, at present there is no literature reported on.The incidence of whole world osteoporosis is in chronic disease
In risen to the 7th, number of patients is more than 200,000,000, and China is up to 90,000,000.It is chronic caused by osteoporotic fracture
Pain, it is disabled or even dead, the quality of life of patient is seriously affected, white elephant is brought to family and society.Bone at present
Matter osteoporosis relies primarily on the treatment of doctor trained in Western medicine chemical synthetic drug, but there are certain side effects.If diphosphonate is clinical
Treat the choice drug of osteoporosis but with increasing upper hemorrhage of lower digestive tract, mandibular festers equivalent risk, Minimally Invasive Surgery therapy,
The treatment of lumbar vertebral body compression fracture is molded in the recent period using balloon expandable centrum, is not operated on, the period, and effect is high；Balloon expandable into
Shape art, percutaneous puncture balloon kyphoplasty are by a pin puncture to fractured vertebral body, establishing service aisle, inciting somebody to action
One special sacculus is put into centrum, makes balloon expandable by pressurization, is resetted the support of the centrum of compression is high, and backed off after random sacculus is by bone water
Mud injects, and strengthens fractured vertebral body, reaches therapeutic purposes.Overall process only needs about 20 minutes, is completed under local anaesthesia, operation safety has
Effect, general second day pain in the back are substantially reduced, you can the out-of-bed activity under brace protection is left hospital for 3-5 days.
In conclusion problem of the existing technology is：Osteoporosis relies primarily on doctor trained in Western medicine chemical synthetic drug at present
Treatment, there are certain side effect, and expensive.
Invention content
In view of the problems of the existing technology, the present invention provides a kind of drugs for treating postmenopausal osteoporosis.
The invention is realized in this way a kind of drug for treating postmenopausal osteoporosis, the raising post menopausal sclerotin is dredged
The drug of loose bone mineral density for circle element bone peptide 10g and Caltrate D 600mg by mass by forming.
The preparation method of the drug of the treatment postmenopausal osteoporosis includes：
Bone gelatin, colloidal sol, enzymolysis, sterilization, cooling, filtering, nanofiltration, high-temperature sterilization, spray drying, semi-finished product splicing,
Semi-finished product detection, packaging, sealing propertytest, finished product detection.
It is a kind of treat postmenopausal osteoporosis drug eating method be：Select 200 milliliters of the warm water of 40--60 degree
Advantages of the present invention and good effect are：Oral gelatine system write from memory joint Caltrate D whether than Caltrate D to post menopausal
Sclerotin pine patient bone loss has better protecting effect project implementation convenience, safety, the economy, with obvious effects, can be into one
The not fixed basis of the loosely-related bone lesion of step research post menopausal sclerotin sulphur, learning value and social benefit are apparent.
The plain bone peptide (foodstuff, non-drug class) of circle of the present invention, it is collagen component, in previous research, more
It is to replenish the calcium, but clinical effect is unsatisfactory.And without the correlative study of collagen, the present invention be first by collagen and calcium into
Row combines, and the absorption of calcium is just more advantageous to absorbing and realize the change of sclerotin, this dredges sclerotin up for being combined with collagen
Pine is especially important, and note of the invention focuses on the analysis and exploitation to collagen.Bone collagen mainly strengthens bone.Gelatine
It is mainly bone collagen element that part is formed in former albumen, it can be such that calcium is effectively deposited on bone, improve the absorptivity of calcium.By
In the loss of collagen, be not fixed easily it is calcareous, so as to cause calcium loss.After coming to one's autumn, bone collagen and calcium largely flow
It loses, influences bone density so as to cause osteoporosis, patient is caused easily to fracture.
Skeleton 2/3 is calcium, and 1/3 is collagen, and just as sponge and water, sponge is exactly the relationship of collagen and calcium
Collagen, calcium is exactly water, indispensable.Most scientific method is that collagen and calcium supplement simultaneously, in this way, calcium could be in glue
It under the bonding of former albumen, is deposited in bone, enhances toughness, the hardness of bone.
Enough collagens are only absorbed, human body there can be calcium normal absorption and utilize, and osteoporosis is asked
Topic can be just addressed.
Description of the drawings
Fig. 1 is the low BMD (left half) of the fragile insufficient calcium binding site of bone collagen matrix provided in an embodiment of the present invention, strong
Big and strong flexible bone collagen stroma, which increases calcium binding site, increases bone density (right half) design sketch.
Specific embodiment
In order to make the purpose , technical scheme and advantage of the present invention be clearer, with reference to embodiments, to the present invention
It is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, it is not used to
Limit the present invention.
Oneself rises to the 7th to the incidence of whole world osteoporosis in chronic disease, and number of patients is more than 200,000,000, and China is
Up to 90,000,000.Chronic pain caused by being fractured due to sclerotin political affairs pine property, disabled or even dead, the serious color life matter for chatting object person
Amount, white elephant is brought to family and society.
The application principle of the present invention is explained in detail below in conjunction with the accompanying drawings.
The drug for the treatment of postmenopausal osteoporosis provided in an embodiment of the present invention is the plain bone peptide of circle and the strange d of calcium that.It is described to carry
The drug of high postmenopausal osteoporotic patients bone density for circle element bone peptide 10g and Caltrate D 600mg by mass by forming.
The application effect of the present invention is explained in detail with reference to embodiment.
Embodiment 1：
1st, screening meets W0 Postmenopausal Osteoporosis diagnostic criteria patient 200, and treatment group takes orally Bone gillg daily
The strange D600mg of 10g Combined with Calcium that, control group take orally Caltrate D 600mg, oral ossein are dredged to post menopausal sclerotin.
2nd, 200 are screened (to meet and be included in, the comprehensive survey of exclusion criteria life style and osteoporosis medicine carries out sclerotin
The basic knowledge education of loss disorders prevention, quantifying diet and exercise therapy, those selected receives Bone gillg Combined with Calcium you is strange at random
D (100 treatment groups) or 6 months pretherapy and post-treatment dual intensity x line absorptions methods of Caltrate D (100 placebos) therapeutic intervention are into controlling
Roche chemoluminescence method is carried out at statistics data into the detection serum skeleton metabolism detection of every trade lumbar spine bmd before and after treatment
Reason, it was therefore concluded that:1) take orally whether Bone gillg joint Caltrate D treatment can significantly improve postmenopausal osteoporotic patients
Bone density 2) take orally whether Bone gillg joint Caltrate D has more postmenopausal osteoporotic patients bone loss than Caltrate D
Good 3. innovative point 1 of improvement result) oral Bone gillg joint Caltrate D treatment can significantly improve postmenopausal osteoporosis trouble
The bone density 2 of person) take orally whether Bone gillg joint Caltrate D has postmenopausal osteoporotic patients bone loss than Caltrate D
There is improvement more.
With reference to concrete analysis, the invention will be further described.
Bone collagen is called tectine matter, is there are one kind of the collagen in human body and animal body, accounts for human body
The 30%-40% of Tot Prot is the main ingredient of human articular cartilage, epiphyseal cartilage and bone trabecula.Have in bone organic matter
More than 80% is ossein.It is that a kind of very special nutriment needed by human and composition skeleton, joint are soft
The important component of each tissue such as bone, tendon, fascia.
The generation of mankind aging and disease is exactly that active ossein is lost in generating as a result, so active ossein is called
" cell culture fluid ", " magma of life ".
Figuratively, the bone soup of family tanning, becomes the flexible substance of jelly sample, this substance is in live body after cooling
In be ossein.It can promote deposition of the inanimate matters such as calcium, phosphorus on bone, thus can play and repair bone tissue, improve bone
The loose symptom of matter, the effect for promoting health.For keep bone toughness, joint it is flexible most important.
Bone collagen is called tectine matter, is there are one kind of the collagen in human body and animal body, accounts for human body
The 30%-40% of Tot Prot is the main ingredient of human articular cartilage, epiphyseal cartilage and bone trabecula.Have in bone organic matter
More than 80% is ossein.It is that a kind of very special nutriment needed by human and composition skeleton, joint are soft
The important component of each tissue such as bone, tendon, fascia.
The generation of mankind aging and disease is exactly that active ossein is lost in generating as a result, so active ossein is called
" cell culture fluid ", " magma of life ".
Figuratively, the bone soup of family tanning, becomes the flexible substance of jelly sample, this substance is in live body after cooling
In be ossein.It can promote deposition of the inanimate matters such as calcium, phosphorus on bone, thus can play and repair bone tissue, improve bone
The loose symptom of matter, the effect for promoting health.For keep bone toughness, joint it is flexible most important.
The active ingredient of circle element bone peptide
Rich in 8 kinds of amino acid needed by human；
Hydroxyproline content is up to 12%；
Peptide content is up to more than 90% in product；The protein accounting of average molecular 500-3000 dalton is up to more than 80%.
Collagen --- " circle element " bone peptide.
2010, the precious biology in east lasted time joint development more than 2 years with Chinese Academy of Sciences's physics and chemistry and goes out " circle element " board small-molecular-weight
Bone collagen peptide is the high-tech product using ox bone as raw material, and product quality indicator reaches international similar product advanced level,
Belong to high-quality collagen product.
At the beginning of 2015, collagen new product " circle element " bone peptide listing, the product uses national inventing patent " soluble glue
Former the protein preparation method " (patent No.：ZL200910241882.X) prepared by orientation enzyme incision technology, saves collagen egg to greatest extent
White bioactivity receives the accreditation and favor of consumer.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
All any modification, equivalent and improvement made within refreshing and principle etc., should all be included in the protection scope of the present invention.
Claims (2)
1. a kind of drug for treating postmenopausal osteoporosis, which is characterized in that it is described treatment postmenopausal osteoporosis drug be:
Circle element bone peptide and Caltrate D.
2. the drug for the treatment of postmenopausal osteoporosis as described in claim 1, which is characterized in that the treatment post menopausal sclerotin
Loose drug, which is characterized in that the element bone peptide of the circle by mass 10g, Caltrate D 600mg.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810057625.XA CN108144039A (en) | 2018-01-22 | 2018-01-22 | A kind of drug for treating postmenopausal osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810057625.XA CN108144039A (en) | 2018-01-22 | 2018-01-22 | A kind of drug for treating postmenopausal osteoporosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108144039A true CN108144039A (en) | 2018-06-12 |
Family
ID=62461795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810057625.XA Pending CN108144039A (en) | 2018-01-22 | 2018-01-22 | A kind of drug for treating postmenopausal osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108144039A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102241733A (en) * | 2011-05-18 | 2011-11-16 | 吉林大学 | Deer ossein polypeptide chelated calcium and enteric capsule and preparation method of enteric capsule |
| CN105903003A (en) * | 2016-05-05 | 2016-08-31 | 中国人民解放军第306医院 | Composition for improving disuse osteoporosis and application of composition |
-
2018
- 2018-01-22 CN CN201810057625.XA patent/CN108144039A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102241733A (en) * | 2011-05-18 | 2011-11-16 | 吉林大学 | Deer ossein polypeptide chelated calcium and enteric capsule and preparation method of enteric capsule |
| CN105903003A (en) * | 2016-05-05 | 2016-08-31 | 中国人民解放军第306医院 | Composition for improving disuse osteoporosis and application of composition |
Non-Patent Citations (3)
| Title |
|---|
| AKRAM KHARROUBI等: "Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women", 《ARCH OSTEOPOROS》 * |
| 薛瑜等: "强化运动、维生素D和钙剂补充对绝经后女性肌力及骨折的影响", 《中国医学科学院学报》 * |
| 贾海琴等: "绿色科技 引领健康时尚", 《海峡科技与产业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101248882A (en) | Nutrition food product with promoting health of bones and bone arthrosis | |
| CN101773663A (en) | New application of collagen chelate | |
| CN108208851A (en) | A kind of five yuan of compound micromolecular collagen peptide powder | |
| CN106262809A (en) | A kind of bone density that strengthens alleviates the compositions of person in middle and old age's arthralgia | |
| CN105903003A (en) | Composition for improving disuse osteoporosis and application of composition | |
| Wan et al. | Intra-articular injection of parathyroid hormone in the temporomandibular joint as a novel therapy for mandibular asymmetry | |
| CN108144039A (en) | A kind of drug for treating postmenopausal osteoporosis | |
| CN101416734A (en) | Health-care products capable of improving skeleton and joint function and preparation method thereof | |
| US8337910B2 (en) | Herbal formulation for the treatment of bone fractures and osseous defects | |
| MILICIC et al. | Effect of fluoride on disuse osteoporosis in the cat | |
| Darwich et al. | Mandibular reconstruction of a hemifacial microsomia using virtual surgical planning and titanium patient specific implant: a case report | |
| KR101878599B1 (en) | Coprecipitation composition for accelerating the absorption and adjustment of the taste of methyl sulfonyl methanemannitol and its preparation method | |
| CN101045140A (en) | Oral liquor with functions of lower blood sugar, lowering blood pressure and relaxing the bowels | |
| Jones | The contribution of microsurgical reconstruction to craniofacial surgery | |
| CN116212007B (en) | Bone-knitting and tendon-softening traditional Chinese medicine composition for treating metaphase fracture and preparation method thereof | |
| CN104888192A (en) | Sea cucumber glucosamine preparation for increasing bone mineral density, and production method thereof | |
| CN1060954C (en) | External use Chinese drug powder and its preparing method and medicinal pad | |
| CN1176668C (en) | Composite biological active capsule and method for preparing the same | |
| CN104324319A (en) | Health-caring product promoting health of bone joint | |
| RU2788898C2 (en) | Method for formation of tissue-engineering composite of bone tissue and periosteum for reconstruction of lower jaw | |
| CN1438006A (en) | medicine for treating orthopedic disease | |
| O'Neal | The pediatric spine: anatomical and dynamic considerations preceding manipulation | |
| CN106729647A (en) | The arthritic collagen ginseng poria compound protein product of one kind preventing and treating | |
| CN110236147A (en) | Halth-care composition, preparation method and its application | |
| Goldstein | Stem cell treatment corrects skull shape and restores brain function in mouse model of childhood disorder. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180612 |
|
| RJ01 | Rejection of invention patent application after publication |